Al-Sawaf, Othman, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Herling, Carmen D., Hoechstetter, Manuela, Fink, Anna-Maria, von Tresckow, Julia, Langerbeins, Petra, Cramer, Paula, Stilgenbauer, Stephan, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2018). Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br. J. Haematol., 183 (5). S. 727 - 736. HOBOKEN: WILEY. ISSN 1365-2141
Full text not available from this repository.Abstract
Clinical management of chronic lymphocytic leukaemia (CLL) in patients aged >= 80 years is based on limited evidence due to the lack of published information. Therefore, we analysed CLL patients aged >= 80 years using data from seven phase III clinical trials of the German CLL Study Group. Among 3552 participants, 152 were >= 80 years old at initiation of first-line study treatment. Median age was 82 years (range 80-90). Concomitant diseases were present in 99% of the patients, with a median cumulative illness rating scale score of 8 (0-18). Chemoimmunotherapy with chlorambucil-obinutuzumab (CLB-OB) or chlorambucil-rituximab (CLB-R) was administered to 61 (40%) and 56 (37%) patients. The remaining patients received CLB (n = 19) or fludarabine (F, n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2) or bendamustine/rituximab (BR, n = 3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%. Overall response rate was 77% with 13% complete remissions. Median progression-free survival and treatment-free survival were 17.2 and 32.3 months, respectively. Median overall survival was 48.3 months; adverse events (22%) and progressive CLL (16.4%) were the most frequent causes of death. These findings suggest that anti-leukaemic treatment including chemoimmunotherapy is feasible and efficacious in >= 80-year-old CLL patients. However, this group of patients lives for a shorter time than age-matched controls of the general population.
| Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URN: | urn:nbn:de:hbz:38-163535 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: | 10.1111/bjh.15604 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Journal or Publication Title: | Br. J. Haematol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 183 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number: | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | S. 727 - 736 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: | 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | WILEY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Place of Publication: | HOBOKEN | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ISSN: | 1365-2141 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Refereed: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/16353 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |